Mitsuo Terada, MD, PhD@乳腺科医· @MamMa_mimumemo · X·· 2 天前评分70
正文
EGFRとHER3のbispecific抗体ADCのPANKU-Breast01試験。HR+MBCの化学療法既治療例が対象。有意にPFSを延長（HR 0.41）。ILDは1.1%。
Lancetに同時掲載。
中国のADC開発の勢いがほんとすごい...
#ESMO26
563 浏览 · 5 赞 · 3 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：Mitsuo Terada, MD, PhD@乳腺科医 · x.com